{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The protocol listed an overall study accrual range of 30 to 37, therefore the study achieved this accrual range (n=31). One patient had an indeterminate response for the primary outcome."},"pointOfContact":{"email":"purdyc@nrgoncology.org","organization":"NRG Oncology","phone":"(716)845-1300","phoneExt":"2296","title":"Christopher Purdy on behalf of Mark Brady PhD"}}